Pharma / Biotech

Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole chalcone as EGFR /Akt pathway inhibitors.



Related Articles

Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole chalcone as EGFR /Akt pathway inhibitors.

Eur J Med Chem. 2018 Dec 08;163:636-648

Authors: Khan I, Garikapati KR, Setti A, Shaik AB, Kanth Makani VK, Shareef MA, Rajpurohit H, Vangara N, Pal-Bhadra M, Kamal A, Kumar CG

Abstract
In an attempt to develop potent and selective anticancer agents, a series of 15 conjugates of 1,4-dihydroindeno[1,2-c]pyrazole chalcone (12a-o) were designed, synthesized and evaluated for their antiproliferative activity against MCF7, A549, MDA-MB-231, HCT116 and SKBR3 human cancer cell lines. Among them, 12h, 12l and 12m showed IC50 values: 3.82, 5.33 and 4.21 μM, respectively, on A549 cell with respect to the positive control, Erlotinib (IC50 value: 10.26 μM). Detailed biological assays showed accumulation of mitotic cells in G2/M phase. In addition, Western blot analysis and immunofluorescence study revealed inhibition of EGFR and Akt pathways. In silico computational studies were also carried out to predict the binding modes and pharmacokinetic parameters of these conjugates.

PMID: 30562699 [PubMed – as supplied by publisher]

Source link




Related posts

Never Too Late to Start Statins for Clogged Leg Arteries

Newsemia

MOMETASONE FUROATE Cream [Glenmark Pharmaceuticals Inc., USA]

Newsemia

clinical pharmacology; +197 new citations

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy